BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30894200)

  • 1. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
    Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
    J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
    Lau D; Magill ST; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
    Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
    Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic pathways and glioblastoma treatment.
    Clarke J; Penas C; Pastori C; Komotar RJ; Bregy A; Shah AH; Wahlestedt C; Ayad NG
    Epigenetics; 2013 Aug; 8(8):785-95. PubMed ID: 23807265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
    Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
    Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy.
    Park EC; Kim G; Jung J; Wang K; Lee S; Jeon SS; Lee ZW; Kim SI; Kim S; Oh YT; Shin JH; Jang HS; Choi BO; Kim GH
    OMICS; 2013 May; 17(5):259-68. PubMed ID: 23586679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
    Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
    Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of EGFR in Paired New and Recurrent Glioblastomas.
    Cioca A; Olteanu EG; Gisca MD; Morosanu CO; Marin I; Florian IS
    Asian Pac J Cancer Prev; 2016; 17(9):4205-4208. PubMed ID: 27797218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
    Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
    J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival kinase genes present prognostic significance in glioblastoma.
    Varghese RT; Liang Y; Guan T; Franck CT; Kelly DF; Sheng Z
    Oncotarget; 2016 Apr; 7(15):20140-51. PubMed ID: 26956052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
    Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
    J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
    Kesari S; Ram Z;
    CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of
    Brandes AA; Franceschi E; Paccapelo A; Tallini G; De Biase D; Ghimenton C; Danieli D; Zunarelli E; Lanza G; Silini EM; Sturiale C; Volpin L; Servadei F; Talacchi A; Fioravanti A; Pia Foschini M; Bartolini S; Pession A; Ermani M
    Oncologist; 2017 Apr; 22(4):432-437. PubMed ID: 28275120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of glioblastoma (GBM) molecular classification methods.
    Lee E; Yong RL; Paddison P; Zhu J
    Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
    Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
    Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal evolution of glioblastoma under therapy.
    Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
    Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.